documents: FDA-2020-N-0026-0030
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | agency_id | docket_id | title | document_type | subtype | posted_date | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2020-N-0026-0030 | FDA | FDA-2020-N-0026 | Issuance of Priority Review Voucher; Rare Pediatric Disease Product; XOLREMDI (mavorixafor) | Notice | Announcement | 2024-05-16T04:00:00Z | 2024 | 5 | 2024-05-16T12:55:40Z | 2024-10715 | 0 | 0 | 0900006486568fbb |
Links from other tables
- 1 row from regs_document_id in fr_regs_crossref